Latest Actavis Inc (ACT) Headlines $ACT
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
Actavis to Host First Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Fri Mar 21, 3:33PM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2014 financial results on Wednesday, April 30, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, April 30, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 17008187.
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
What Makes Tenet (THC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:54AM CDT
It may be a good decision to sell Tenet as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Gentherm, Kors Setting Up in Tight Formations
at Investor's Business Daily - Thu Mar 20, 5:01PM CDT
Several leaders showing up in the Stock Spotlight have been moving sideways in a tight fashion. That should be considered bullish. If a stock advances, then moves sideways, it means sellers are nowhere in sight and institutional buyers consider even...
New Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:45PM CDT
Pacira released new data from two studies evaluating the use of Exparel to manage postsurgical pain following total joint arthroplasty.
Actavis Announces Daytrana® Patent Challenge Settlement
PR Newswire - Wed Mar 19, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana® (Methylphenidate Transdermal System). Daytrana® is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Horizon Pharma To Buy Vidara, Join Exodus To Ireland
at Investor's Business Daily - Wed Mar 19, 9:45AM CDT
Horizon Pharma (HZNP) followed many of its fellow drugmakers to Ireland Wednesday as it agreed to buy Dublin-based Vidara Therapeutics in a deal worth $660 million. Horizon shares jumped 17% in the stock market today, hitting an all-time high....
Mixed News for Pfizer: A Good Chance to Buy?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:30AM CDT
Last week was unusually eventful for Pfizer . The company, along with partner Bristol-Myers Squibb won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from a pneumonia vaccine study that...
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 17, 5:35PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Are We in the Midst of Irrational Exuberance Version 2.0?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 16, 11:10AM CDT
" Clearly, sustained low inflation implies less uncertainty about the future, and lower risk premiums imply higher prices of stocks and other earning assets. We can see that in the inverse relationship exhibited by price/earnings ratios and the rate...
Investors Don't Celebrate Celebrex Decision Favoring Cheap Generics
David Williamson, The Motley Fool - Motley Fool - Sun Mar 16, 7:00AM CDT
Biotech investors are no stranger to a trading halt that brings game-changing news to a stock, but you don't see it very often when it comes to big pharmaceutical companies, especially ones with $200 billion market caps. So it came as a surprise...
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:20PM CDT
Both Actavis and Mylan are looking to launch their generic versions of Celebrex in May provided they gain final FDA approval.
Horizon Pharma Banks On Two-For-One Arthritis Drugs
at Investor's Business Daily - Fri Mar 14, 1:05PM CDT
Specialty drug company Horizon Pharma (HZNP) is on a roll with two arthritis drugs, Duexis and Vimovo. Both treat arthritis pain and protect against ulcers, a two-for-one bang that most other drugs treating arthritis don't provide. Like most...
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 5:00PM CDT
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.
Stocks Down 1% In Late Afternoon As Volume Picks Up
at Investor's Business Daily - Thu Mar 13, 2:54PM CDT
Stocks were down 1% or more late Thursday afternoon as ongoing worries about China and Ukraine trumped better-than-expected U.S. economic data. The Nasdaq slumped 1.4%, the Dow Jones industrial average lost 1.2%, with 28 of 30 issues lower. The S&P...
Is the Market Undervaluing Celgene?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 13, 1:30PM CDT
Celgene admittedly does not leap off the page as a cheap stock, at least not with a cursory glance. The shares are up about 40% over the past year (and more than 100% over the past two years) and trade at more than nine times sales and 11 times...
Narrower-than-Expected Loss at Supernus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:40AM CDT
Supernus reported 4Q13 net loss per share of 39 cents, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
Actavis to Host First Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Fri Mar 21, 3:33PM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2014 financial results on Wednesday, April 30, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, April 30, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 17008187.
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
What Makes Tenet (THC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:54AM CDT
It may be a good decision to sell Tenet as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Gentherm, Kors Setting Up in Tight Formations
at Investor's Business Daily - Thu Mar 20, 5:01PM CDT
Several leaders showing up in the Stock Spotlight have been moving sideways in a tight fashion. That should be considered bullish. If a stock advances, then moves sideways, it means sellers are nowhere in sight and institutional buyers consider even...
New Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:45PM CDT
Pacira released new data from two studies evaluating the use of Exparel to manage postsurgical pain following total joint arthroplasty.
Actavis Announces Daytrana® Patent Challenge Settlement
PR Newswire - Wed Mar 19, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana® (Methylphenidate Transdermal System). Daytrana® is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Horizon Pharma To Buy Vidara, Join Exodus To Ireland
at Investor's Business Daily - Wed Mar 19, 9:45AM CDT
Horizon Pharma (HZNP) followed many of its fellow drugmakers to Ireland Wednesday as it agreed to buy Dublin-based Vidara Therapeutics in a deal worth $660 million. Horizon shares jumped 17% in the stock market today, hitting an all-time high....
Mixed News for Pfizer: A Good Chance to Buy?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:30AM CDT
Last week was unusually eventful for Pfizer . The company, along with partner Bristol-Myers Squibb won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from a pneumonia vaccine study that...
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 17, 5:35PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Are We in the Midst of Irrational Exuberance Version 2.0?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 16, 11:10AM CDT
" Clearly, sustained low inflation implies less uncertainty about the future, and lower risk premiums imply higher prices of stocks and other earning assets. We can see that in the inverse relationship exhibited by price/earnings ratios and the rate...
Investors Don't Celebrate Celebrex Decision Favoring Cheap Generics
David Williamson, The Motley Fool - Motley Fool - Sun Mar 16, 7:00AM CDT
Biotech investors are no stranger to a trading halt that brings game-changing news to a stock, but you don't see it very often when it comes to big pharmaceutical companies, especially ones with $200 billion market caps. So it came as a surprise...
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:20PM CDT
Both Actavis and Mylan are looking to launch their generic versions of Celebrex in May provided they gain final FDA approval.
Horizon Pharma Banks On Two-For-One Arthritis Drugs
at Investor's Business Daily - Fri Mar 14, 1:05PM CDT
Specialty drug company Horizon Pharma (HZNP) is on a roll with two arthritis drugs, Duexis and Vimovo. Both treat arthritis pain and protect against ulcers, a two-for-one bang that most other drugs treating arthritis don't provide. Like most...
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 5:00PM CDT
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.
Stocks Down 1% In Late Afternoon As Volume Picks Up
at Investor's Business Daily - Thu Mar 13, 2:54PM CDT
Stocks were down 1% or more late Thursday afternoon as ongoing worries about China and Ukraine trumped better-than-expected U.S. economic data. The Nasdaq slumped 1.4%, the Dow Jones industrial average lost 1.2%, with 28 of 30 issues lower. The S&P...
Is the Market Undervaluing Celgene?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 13, 1:30PM CDT
Celgene admittedly does not leap off the page as a cheap stock, at least not with a cursory glance. The shares are up about 40% over the past year (and more than 100% over the past two years) and trade at more than nine times sales and 11 times...
Narrower-than-Expected Loss at Supernus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:40AM CDT
Supernus reported 4Q13 net loss per share of 39 cents, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
